Journal Watch · Journal of Medicinal Chemistry · 2026

Design and Synthesis of Type-A Proanthocyanidin Derivatives as JAK2 Activators to Protect against Chemotherapy-Induced Myelosuppression.

These findings identify 32 as a promising orally available JAK2 activator for CIM treatment.

Qian J, Wang R, Lei W et al.Journal of Medicinal Chemistry3 min readPharma relevance 50/100

DOI: 10.1021/acs.jmedchem.6c01091PMID: 42593935Study type: preclinical (animal / model) study

TL;DR

These findings identify 32 as a promising orally available JAK2 activator for CIM treatment.

Key findings

  • In primary BMHSCs, 32 activated the JAK2/STAT3 pathway and alleviated carboplatin-induced damage.
  • Consistently, oral administration of 32 at 50 mg/kg activated JAK2/STAT3 signaling in vivo and promoted hematopoietic recovery in CIM mice, with favorable bioavailability and acceptable preliminary safety.
  • These findings identify 32 as a promising orally available JAK2 activator for CIM treatment.

What they did

Here, a series of Type-A proanthocyanidin derivatives (5-35) were designed, synthesized, and evaluated for JAK2 activation, leading to the identification of compound 32 as the most potent activator (EC50 = 64 nM). Target-binding assays demonstrated that 32 directly bound JAK2 and displayed preferential affinity for the JH2 pseudokinase domain over the JH1 catalytic domain, indicating a potential JH2-mediated activation mechanism.

Full abstract (original)

Background: Chemotherapy-induced myelosuppression (CIM) significantly impairs hematopoiesis. Proanthocyanidin A1 (1) from peanut skin is a JAK2 activator to alleviate CIM, but the SAR and drug-like properties of Type-A proanthocyanidins remain unclear.

What they did: Here, a series of Type-A proanthocyanidin derivatives (5-35) were designed, synthesized, and evaluated for JAK2 activation, leading to the identification of compound 32 as the most potent activator (EC50 = 64 nM). Target-binding assays demonstrated that 32 directly bound JAK2 and displayed preferential affinity for the JH2 pseudokinase domain over the JH1 catalytic domain, indicating a potential JH2-mediated activation mechanism.

Results & conclusions: In primary BMHSCs, 32 activated the JAK2/STAT3 pathway and alleviated carboplatin-induced damage. Consistently, oral administration of 32 at 50 mg/kg activated JAK2/STAT3 signaling in vivo and promoted hematopoietic recovery in CIM mice, with favorable bioavailability and acceptable preliminary safety. These findings identify 32 as a promising orally available JAK2 activator for CIM treatment.

Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c01091 · PubMed 42593935.

Why it matters for pharma & biotech

  • Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
  • The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
  • The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.

Frequently asked questions

What did this Journal of Medicinal Chemistry study find?

These findings identify 32 as a promising orally available JAK2 activator for CIM treatment.

What type of study is this?

It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. Here, a series of Type-A proanthocyanidin derivatives (5-35) were designed, synthesized, and evaluated for JAK2 activation, leading to the identification of compound 32 as the most potent activator (EC50 = 64 nM).

Where can I read the original paper?

The original is at the publisher via DOI 10.1021/acs.jmedchem.6c01091. PubMed ID: 42593935. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Qian J, Wang R, Lei W et al.. Design and Synthesis of Type-A Proanthocyanidin Derivatives as JAK2 Activators to Protect against Chemotherapy-Induced Myelosuppression.. Journal of Medicinal Chemistry (2026). DOI: 10.1021/acs.jmedchem.6c01091.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/design-and-synthesis-of-type-a-proanthocyanidin-derivatives-as-jak2-acti-c01091/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides